IPP Bureau
ADC Therapeutics appoints David Gilman as Chief Business & Strategy Officer
By IPP Bureau - June 15, 2022
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Eli Lilly gets FDA approval for alopecia drug
By IPP Bureau - June 15, 2022
Alopecia areata usually presents as a few small bald patches in the head
InfuSystem and Ventis ink sales agreement for pain management
By IPP Bureau - June 15, 2022
The company will offer Ventis Pharma’s patented local anesthetic compound, Endura-KitTM for post-operative surgical and chronic pain management
Etihad Cargo signs MOU for sustainable pharmaceutical transportation solutions
By IPP Bureau - June 15, 2022
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
By IPP Bureau - June 15, 2022
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
CCI approves acquisition of corporate restructuring of GlaxoSmithKline Consumer Healthcare
By IPP Bureau - June 15, 2022
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
NHA and NASSCOM organised a conclave on Ayushman Bharat Digital Mission
By IPP Bureau - June 15, 2022
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
COVID is not over yet, says Union Health Minister
By IPP Bureau - June 14, 2022
Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community
Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022
By IPP Bureau - June 14, 2022
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Philips announces positive research results from its TOBA II BTK clinical trial
By IPP Bureau - June 14, 2022
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
.png "Thermo Fisher Scientific launches new MS-based solutions")
Thermo Fisher Scientific launches new MS-based solutions
By IPP Bureau - June 14, 2022
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
By IPP Bureau - June 14, 2022
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma
By IPP Bureau - June 14, 2022
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants
By IPP Bureau - June 14, 2022
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Karkinos Healthcare launched ‘Advanced Center for Cancer Diagnostics and Research’
By IPP Bureau - June 12, 2022
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
